Novartis
(https://pluvicto.com) 📸 Data Snapshot: May 30, 2026Count trust words (review, testimonial, rating, verified) against real outbound proof links (Google, Trustpilot, Clutch, G2, Yelp). Lots of trust language with zero verification links is trust theatre. Unlinked logo galleries count against it.
Trust theatre is nearly non-existent, though a review_count of 1 is detected on the PLUVICTO Pulse page without an accompanying testimonial text. However, this is heavily outweighed by the presence of verifiable proof links including NDC codes (69488-0010-61), FDA prescribing information PDFs, and ClinicalTrials.gov references. The site relies on clinical evidence rather than social proof theatre.
The proof density is top-tier, with a high ratio of verifiable technical data to marketing assertions. The site provides specific NDC numbers, strength values (200.00 mCl), and a detailed dose schedule (every six weeks for up to six cycles). Generic assertions are minimized in favor of regulatory-compliant specifications.
Trust & Proof is read by weighing trust language against real verification. Below is the page-by-page tally of review mentions and external proof links, then the schema markup that may (or may not) declare verifiable ratings and identity proof.
🛡️ Trust Signals — reviews, proof links, trust-theatre check
| Page | Reviews | Proof links |
|---|---|---|
| / (home) | 0 | 0 |
| /about-pluvicto/how-pluvicto-works/ | 0 | 0 |
| /treatment-center-locator/ | 0 | 0 |
| /pluvicto-pulse/ | 1 | 0 |
🔗 Identity & Technical Layer — schema JSON-LD: declared ratings, reviews & identity proof
Homepage schema
{
"@context": "https://schema.org",
"@type": "Organization",
"@id": "https://us.pluvicto.com/#Organization",
"name": "Novartis",
"url": "https://www.novartis.com/us-en/",
"logo": "https://usim.beprod.us.pluvicto.com/sites/us_pluvicto_com/files/icons/2025-10/logo.svg",
"description": "Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.",
"makesOffer": {
"@type": "Offer",
"@id": "https://us.pluvicto.com/#makesOffer",
"name": "Pluvicto",
"alternateName": "Lutetium Lu 177 vipivotide tetraxetan",
"availability": "https://schema.org/PrescriptionOnly",
"sameAs": "https://us.pluvicto.com/about-pluvicto/how-pluvicto-may-help#offerPluvicto"
}
}
/about-pluvicto/how-pluvicto-works/
{
"@context": "https://schema.org",
"@type": "medicalGuideline",
"@id": "https://us.pluvicto.com/about-pluvicto/how-pluvicto-works#medicalGuideline",
"url": "https://us.pluvicto.com/about-pluvicto/how-pluvicto-works",
"name": "Pluvicto's metastatic Castration-Resistant Prostate Cancer (mCRPC) Medical Guideline",
"legalStatus": "Prescription only, FDA approved",
"description": "Learn about metastatic castration-resistant prostate cancer (mCRPC) and how to find out if you are PSMA+. See full Prescribing and Safety Information.",
"guidelineSubject": {
"@type": "drugClass",
"@id": "https://us.pluvicto.com/about-pluvicto/how-pluvicto-works#drugClass",
"url": "https://us.pluvicto.com/about-pluvicto/how-pluvicto-works",
"description": "PLUVICTO is a prescription treatment used to treat adults with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) already treated with hormon therapy or hormone therapy and chemotherapy",
"drug": {
"@type": "drug",
"@id": "https://us.pluvicto.com/about-pluvicto/how-pluvicto-may-help#drug",
"image": "https://usim.beprod.us.pluvicto.com/sites/us_pluvicto_com/files/icons/2025-10/psma617_pluvicto_r_rgb_us-2.jpg",
"name": "Pluvicto",
"prescribingInfo": "https://www.novartis.com/us-en/sites/novartis_us/files/pluvicto.pdf",
"sameAs": [
"https://en.wikipedia.org/wiki/Lu-PSMA-617",
"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf",
"https://www.novartis.com/us-en/sites/novartis_us/files/pluvicto.pdf",
"https://www.cancer.org/cancer/types/prostate-cancer/treating/radiation-therapy.html",
"https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fb973a8d-7fea-4a7a-963f-2a8e67a46e55"
],
"warning": [
"https://www.novartis.com/us-en/sites/novartis_us/files/pluvicto.pdf",
"low level of blood cell counts",
"tiredness or weakness",
"pale skin",
"shortness of breath",
"bleeding or bruising",
"kidney problems",
"pregnancy complications",
"infertility",
"headache",
"tiredness",
"dry mouth",
"nausea",
"appetite loss",
"join pain",
"constipation",
"back pain"
],
"mechanismOfAction": "https://us.pluvicto.com/about-pluvicto/how-pluvicto-works#mechanismOfAction",
"dosageForm": "Injection",
"availableStrength": {
"@type": "drugStrength",
"activeIngredient": "Lutetium Lu 177 vipivotide tetraxetan",
"sameAs": [
"https://en.wikipedia.org/wiki/Lu-PSMA-617",
"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf",
"https://www.novartis.com/us-en/sites/novartis_us/files/pluvicto.pdf",
"https://medlineplus.gov/druginfo/meds/a622063.html",
"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/lutetium-lu-177-vipivotide-tetraxetan"
],
"strengthUnit": "mCl",
"strengthValue": "200.00"
},
"identifier": {
"@type": "PropertyValue",
"name": "NDC",
"description": "US National Drug Codes",
"sameAs": [
"https://www.novartis.com/us-en/sites/novartis_us/files/pluvicto.pdf",
"https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fb973a8d-7fea-4a7a-963f-2a8e67a46e55",
"https://seer.cancer.gov/oncologytoolbox/canmed/ndconc/69488-0010/",
"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-expands-pluvictos-metastatic-castration-resistant-prostate-cancer-indication"
],
"value": "69488-0010-61"
},
"doseSchedule": {
"@type": "doseSchedule",
"@id": "https://us.pluvicto.com/about-pluvicto/what-to-expect-with-pluvicto-treatment#doseSchedule",
"doseUnit": "mCl",
"doseValue": "200.00",
"frequency": "Consult Physician",
"description": "Refer to the Full Prescribing Information for the recommended dosage. The recommended PLUVICTO dosage is one dose taken intraveneously every six weeks for up to six treatment cycles. "
},
"offers": {
"@type": "Offer",
"@id": "https://us.pluvicto.com/about-pluvicto/how-pluvicto-may-help#offerPluvicto",
"availability": "LimitedAvailability",
"image": "https://usim.beprod.us.pluvicto.com/sites/us_pluvicto_com/files/icons/2025-10/psma617_pluvicto_r_rgb_us-2.jpg",
"priceValidUntil": "2025-12-31",
"url": "https://us.pluvicto.com/about-pluvicto/how-pluvicto-may-help#offerPluvicto",
"price": "50164.84",
"priceCurrency": "USD"
}
}
}
}
This page presents a snapshot of public data from Novartis, captured on May 30, 2026, to show how machine logic reads Trust & Proof signals into an AI reputation evaluation.
Purpose: This data is presented under “Fair Use” for the purpose of independent signal analysis, allowing readers to see the raw signals behind the reputation score.
Notice to Novartis: This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results are intended as professional feedback to help improve any website’s machine-readability and authority signals. The evaluation is free, and any company can request a fresh audit at any time.
Any company can use the insights for free and improve its voice. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://pluvicto.com to view the most current version of its content and see directly what this company is about and what it offers.